France· FR:68806037
METYRAPONE ESTEVE 250 mg, capsule molle
A metyrapone product containing métyrapone, registered in France by ESTEVE PHARMACEUTICALS (ESPAGNE), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Metyrapone is registered in 14 of 19 countries.
Countries holding a registration under ATC V04CD01 (metyrapone), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Metyrapone · ATC V04CD01
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of metyrapone costs, country by country.
Normalised to the WHO defined daily dose (3 g), so markets compare like for like.
- France: $70.58 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Metyrapone · price per daily dose (3 g)
USD · FX 28 Sept 2026
- CH Switzerland$91.87
- FR France$70.58
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MÉTYRAPONE
- Manufacturer
- ESTEVE PHARMACEUTICALS (ESPAGNE)
- Country
- France (FR)
- ATC code
- V04CD01
- ATC class
- Metyrapone
- Defined daily dose
- 3 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930007327flacon(s) polyéthylène haute densité (PEHD) de 50 capsule(s)EUR 258.31
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
14 interactions on record for metyrapone.
Graded by severity as the source publishes them — 14 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metyrapone · interactions on record
14 records
- 14 moderate
Most severe, free to view
- CyproheptadinA15AA01moderate
- EstradiolD11AX34moderate
- Levonorgestrel and ethinylestradiolG03AA07moderate
- Desogestrel and ethinylestradiolG03AA09moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Metyrapone in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaMETOPIRONEEsteve Pharmaceuticals S.A., Barcelona
- SpainMETOPIRONE 250 MG CAPSULAS BLANDASEsteve Pharmaceuticals S.A.
- FinlandMetopironeEsteve Pharmaceuticals S.A.S.
- IrelandMetopirone 250 mg soft capsulesEsteve Pharmaceuticals S.A.
- NorwayMetycorEsteve Pharmaceuticals S.A
- PolandMetopironeEsteve Pharmaceuticals, S.A.
- BelgiumMetycor 250 mgHRA Pharma France
- SwedenMetopirone 250 mg Kapsel, mjukEsteve Pharmaceuticals S.A.
Authorised across Europe · EMA
The same active substance is authorised in 23 EEA countries. Names it is sold under:
- Austria · Metycor
- Bulgaria · Metopirone
- Czechia · Metopirone
- Germany · Metopiron
- Denmark · Metopirone
- Estonia · Cormeto
- Spain · Metopirone
- Finland · Metopirone
- Greece · Metopirone
- Croatia · Metopirone
- Hungary · Cormeto
- Ireland · Metopirone
- Italy · Cormeto
- Lithuania · Cormeto
- Latvia · Metopirone
- Netherlands · Metopirone
- Norway · Metycor
- Poland · Metopirone
- Portugal · Metopirone Esteve Pharmaceuticals
- Romania · Metopirone
- Sweden · Metopirone
- Slovenia · Metycor
- Slovakia · Metopirone
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a7e3aab7-0c21-44d1-b022-dbb6e3ef9aea GET /v1/drugs/a7e3aab7-0c21-44d1-b022-dbb6e3ef9aea?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68806037",
"date_amm": "2015-02-05",
"type_amm": "Procédure de reconnaissance mutuelle",
"numero_ue": null,
"substance": "MÉTYRAPONE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "capsule molle",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about metyrapone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.